300 related articles for article (PubMed ID: 8743538)
1. C-type natriuretic peptide in chronic renal failure and its action in humans.
Igaki T; Itoh H; Suga S; Hama N; Ogawa Y; Komatsu Y; Mukoyama M; Sugawara A; Yoshimasa T; Tanaka I; Nakao K
Kidney Int Suppl; 1996 Jun; 55():S144-7. PubMed ID: 8743538
[TBL] [Abstract][Full Text] [Related]
2. Detection of C-type natriuretic peptide in human circulation and marked increase of plasma CNP level in septic shock patients.
Hama N; Itoh H; Shirakami G; Suga S; Komatsu Y; Yoshimasa T; Tanaka I; Mori K; Nakao K
Biochem Biophys Res Commun; 1994 Feb; 198(3):1177-82. PubMed ID: 8117275
[TBL] [Abstract][Full Text] [Related]
3. Activation of myocardial and renal natriuretic peptides during acute intravascular volume overload in dogs: functional cardiorenal responses to receptor antagonism.
Borgeson DD; Stevens TL; Heublein DM; Matsuda Y; Burnett JC
Clin Sci (Lond); 1998 Aug; 95(2):195-202. PubMed ID: 9680502
[TBL] [Abstract][Full Text] [Related]
4. Human C-type natriuretic peptide: effects on the haemodynamic and endocrine responses to angiotensin II.
Cargill RI; Struthers AD; Lipworth BJ
Cardiovasc Res; 1995 Jan; 29(1):108-11. PubMed ID: 7895227
[TBL] [Abstract][Full Text] [Related]
5. Effects of intravenously administered C-type natriuretic peptide in humans: comparison with atrial natriuretic peptide.
Igaki T; Itoh H; Suga SI; Hama N; Ogawa Y; Komatsu Y; Yamashita J; Doi K; Chun TH; Nakao K
Hypertens Res; 1998 Mar; 21(1):7-13. PubMed ID: 9582102
[TBL] [Abstract][Full Text] [Related]
6. Bolus injections of synthetic atrial natriuretic peptide in patients with chronic renal failure or nephrotic syndrome.
Burnier M; Mooser V; Wauters JP; Marder HK; De Vane P; Nussberger J; Waeber B; Brunner HR
J Cardiovasc Pharmacol; 1989 May; 13(5):682-90. PubMed ID: 2472515
[TBL] [Abstract][Full Text] [Related]
7. Pressure-dependent distal tubular action of atrial natriuretic peptide in healthy humans.
Eiskjaer H; Nielsen CB; Pedersen EB
J Hypertens; 1996 Jan; 14(1):99-106. PubMed ID: 12013501
[TBL] [Abstract][Full Text] [Related]
8. Bioactivity and metabolism of C-type natriuretic peptide in normal man.
Hunt PJ; Richards AM; Espiner EA; Nicholls MG; Yandle TG
J Clin Endocrinol Metab; 1994 Jun; 78(6):1428-35. PubMed ID: 8200946
[TBL] [Abstract][Full Text] [Related]
9. Effect of exercise on natriuretic peptides in plasma and urine in chronic heart failure.
Bentzen H; Pedersen RS; Nyvad O; Pedersen EB
Int J Cardiol; 2004 Feb; 93(2-3):121-30. PubMed ID: 14975537
[TBL] [Abstract][Full Text] [Related]
10. Plasma concentrations of natriuretic peptides in patients on hemodialysis.
Takahashi M; Nagake Y; Ichikawa H; Kawabata K; Nakazono H; Hirata K; Ogura T; Makino H
Res Commun Mol Pathol Pharmacol; 1996 Apr; 92(1):19-30. PubMed ID: 8733825
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis of heart failure using urinary natriuretic peptides.
Ng LL; Geeranavar S; Jennings SC; Loke I; O'Brien RJ
Clin Sci (Lond); 2004 Feb; 106(2):129-33. PubMed ID: 13678415
[TBL] [Abstract][Full Text] [Related]
12. Plasma brain natriuretic peptide and C-type natriuretic peptide in essential hypertension.
Cheung BM; Brown MJ
J Hypertens; 1994 Apr; 12(4):449-54. PubMed ID: 8064169
[TBL] [Abstract][Full Text] [Related]
13. Expression of natriuretic peptide system during embryonic stem cell vasculogenesis.
Doi K; Itoh H; Nakagawa O; Igaki T; Yamashita J; Chun TH; Inoue M; Masatsugu K; Nakao K
Heart Vessels; 1997; Suppl 12():18-22. PubMed ID: 9476535
[TBL] [Abstract][Full Text] [Related]
14. Differential regulation of brain and atrial natriuretic peptides in hemodialysis patients.
Kohse KP; Feifel K; Mayer-Wehrstein R
Clin Nephrol; 1993 Aug; 40(2):83-90. PubMed ID: 8222377
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular and renal effects of low-dose atrial natriuretic peptide in compensated cirrhosis.
La Villa G; Lazzeri C; Pascale A; Sestini S; Bisi G; Sciagrà R; Vecchiarino S; Raggi VC; Barletta G; Laffi G; Gentilini P
Am J Gastroenterol; 1997 May; 92(5):852-7. PubMed ID: 9149200
[TBL] [Abstract][Full Text] [Related]
16. Plasma human brain natriuretic peptide in chronic renal failure.
Akiba T; Tachibana K; Togashi K; Hiroe M; Marumo F
Clin Nephrol; 1995 Nov; 44 Suppl 1():S61-4. PubMed ID: 8608666
[TBL] [Abstract][Full Text] [Related]
17. C-type natriuretic peptide production by the human kidney is blunted in chronic heart failure.
Kalra PR; Clague JR; Coats AJ; Anker SD; Poole-Wilson PA; Struthers AD
Clin Sci (Lond); 2009 Oct; 118(1):71-7. PubMed ID: 19450232
[TBL] [Abstract][Full Text] [Related]
18. Comparative bioactivity of atrial, brain, and C-type natriuretic peptides in conscious sheep.
Charles CJ; Espiner EA; Richards AM; Nicholls MG; Yandle TG
Am J Physiol; 1996 Jun; 270(6 Pt 2):R1324-31. PubMed ID: 8764300
[TBL] [Abstract][Full Text] [Related]
19. Which of the cardiac natriuretic peptides is most effective for the treatment of congestive heart failure, renal failure and cancer?
Vesely DL
Clin Exp Pharmacol Physiol; 2006 Mar; 33(3):169-76. PubMed ID: 16487258
[TBL] [Abstract][Full Text] [Related]
20. C-type natriuretic peptide: the endothelial component of the natriuretic peptide system.
Chen HH; Burnett JC
J Cardiovasc Pharmacol; 1998; 32 Suppl 3():S22-8. PubMed ID: 9883743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
